Skip to main content

04-06-2019 | Castration-sensitive prostate cancer | Video | Article

Expert comment: ENZAMET and TITAN trials

Earle Burgess provides an independent commentary on the ENZAMET and TITAN results presented at the 2019 ASCO Annual Meeting, and discusses what these data mean for patients and physicians (2:57).

Related topics

More on this topic

Image Credits